Foghorn Therapeutics Inc.
NASDAQ:FHTX
8.86 (USD) • At close November 12, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Foghorn Therapeutics Inc. |
Symbool | FHTX |
Munteenheid | USD |
Prijs | 8.86 |
Beurswaarde | 492,554,866 |
Dividendpercentage | 0% |
52-weken bereik | 2.7 - 10.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Adrian H. B. Gottschalk |
Website | https://foghorntx.com |
An error occurred while fetching data.
Over Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)